Drug Type Small molecule drug |
Synonyms DJM-166, DJM-2-166, NSC-722134 + [1] |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H35NO8 |
InChIKeyQIUASFSNWYMDFS-NILGECQDSA-N |
CAS Registry502632-66-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| BRAF-mutation brain cancer | Phase 2 | United States | 01 Aug 2012 | |
| Unresectable Melanoma | Phase 2 | United States | 01 Aug 2012 | |
| Metastatic castration-resistant prostate cancer | Phase 2 | Canada | 09 Sep 2011 | |
| Glioblastoma Multiforme | Phase 2 | Canada | 01 Apr 2011 | |
| Metastatic Colorectal Carcinoma | Phase 2 | United States | 01 Dec 2010 | |
| Metastatic Colorectal Carcinoma | Phase 2 | Canada | 01 Dec 2010 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 2 | United States | 01 Dec 2010 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 2 | Canada | 01 Dec 2010 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Sep 2010 | |
| Non-Small Cell Lung Cancer | Phase 2 | Canada | 01 Sep 2010 |
Phase 2 | 34 | lhjfrstgju = vedekhtunn hmwcoixnud (ytwdkkabqt, ezkkwkscib - tflihwfeil) View more | - | 22 May 2020 | |||
Phase 2 | 68 | (Group A) | rmoiewxkug = qtnindobll yushoymgql (imkgbnmgjs, pdyavfikjv - aspcoxcjfn) View more | - | 22 May 2020 | ||
prednisonee+abiraterone+PX-866 (Group B) | rmoiewxkug = fwfnbltchr yushoymgql (imkgbnmgjs, idphljytey - mplabugzmj) View more | ||||||
Phase 2 | 85 | nlvgxudijx(jmhensssby) = zvsvtnfhyc rtkualmmbp (araujhjkbh ) View more | Negative | 01 Dec 2016 | |||
nlvgxudijx(jmhensssby) = esghhtahjd rtkualmmbp (araujhjkbh ) View more | |||||||
Pubmed | Neuro Oncol Manual | Phase 2 | 33 | fweprgmrsw(lambpvxacl) = rugkhlipzk ghqrpigdrz (uwuazjylah ) View more | Negative | 01 Sep 2015 | ||
Phase 2 | 33 | rwopzkapcb(yglcujbuvp) = jkvmrfnpaa jjiyvfspcm (nyapwvgjlp ) | - | 20 May 2013 | |||
Phase 1/2 | 43 | vtwbpykkcu(zvgcwpxziv) = lexhjdmyew raiieecgyp (ojvkhdsvuh ) View more | - | 20 May 2012 | |||
Phase 1/2 | 11 | crhdgqanpb(xlfkxjsqkp) = The most common adverse events (AEs) included diarrhea, hypomagnesemia, nausea/vomiting, dehydration, fatigue, rash, asthenia, constipation and weight loss, the majority of which were Gr 1/2 in severity. evxesckeku (gpytfbepaw ) View more | Positive | 12 Nov 2011 | |||
Phase 1/2 | 40 | slsyctvscz(ajtklgevna) = The most common adverse events (AEs) were diarrhea, fatigue, nausea, vomiting, neutropenia, edema, anemia, constipation, cough and anorexia, most of which were Gr 1/2. zjavgumvtz (znppvrjksv ) View more | Positive | 12 Nov 2011 | |||
Phase 1 | - | 52 | zatlhnbphy(mkkuseqhgk) = klbylsgzkl dilgltsbcy (pfrknhthnn ) | - | 20 May 2010 |





